Anther important feature of NSC-631570 is the inhibition of the formation of the new blood vessels supplying a tumor. Due to these antiangiogenic properties NSC-631570 administered before surgery brings about better demarcation of the tumor from surrounding tissue and the tumor encapsulation. This alleviates the surgical removal of tumors what has been confirmed in breast cancer studies [67, 71, 103-106, 140]. In tests \textit{in vitro}, NSC-631570 inhibited in a dose-dependent manner the proliferation of human endothelial cells without exerting cytotoxic effect. The angiogenesis inhibition was observed on the capillary formation model [134]. This inhibition of the neoangiogenesis prevents the metastasis formation as well.

Fig. 7. The length of the total capillary tubes after the incubation with NSC-631570 in given concentrations. 1 – HUVEC were incubated with NSC-631570 for 4 h. 2 – HUVEC were preincubated with NSC-631570 for 4h and then incubated for 2 h in fresh medium without NSC-631570. HUVEC – human umbilical vein endothelial cells. From: [134].

\textbf{Biography}

Wassil Nowicky obtained Diploma and is the Director of "Nowicky Pharma" and President of the Ukrainian Anti-Cancer Institute (Vienna, Austria). He has finished his study at the Radiotechnical Faculty of the Technical University of Lviv (Ukraine) with the end of 1955 with graduation to "Diplomingeniueur" in 1960 which title was nostrificated in Austria in 1975. He is the inventor of the anti-cancer preparation on basis of celandine alkaloids "NSC-631570".

\texttt{dr.nowicky@yahoo.de}

\textbf{Notes:}